• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GRI

    GRI Bio Inc.

    Subscribe to $GRI
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for GRI Bio Inc.

    DatePrice TargetRatingAnalyst
    12/9/2024$10.00Buy
    H.C. Wainwright
    See more ratings

    GRI Bio Inc. SEC Filings

    See more
    • GRI Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GRI Bio, Inc. (0001824293) (Filer)

      5/23/25 7:16:47 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by GRI Bio Inc.

      424B5 - GRI Bio, Inc. (0001824293) (Filer)

      5/23/25 7:14:51 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by GRI Bio Inc.

      10-Q - GRI Bio, Inc. (0001824293) (Filer)

      5/15/25 8:38:34 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GRI Bio, Inc. (0001824293) (Filer)

      5/15/25 8:35:54 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GRI Bio, Inc. (0001824293) (Filer)

      5/5/25 7:35:49 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by GRI Bio Inc.

      424B5 - GRI Bio, Inc. (0001824293) (Filer)

      5/5/25 7:35:23 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - GRI Bio, Inc. (0001824293) (Filer)

      4/15/25 6:14:17 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by GRI Bio Inc.

      SCHEDULE 13G - GRI Bio, Inc. (0001824293) (Subject)

      4/7/25 4:17:11 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by GRI Bio Inc.

      424B4 - GRI Bio, Inc. (0001824293) (Filer)

      4/2/25 8:32:07 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - GRI Bio, Inc. (0001824293) (Filer)

      4/2/25 8:29:59 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    GRI Bio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on GRI Bio with a new price target

      H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00

      12/9/24 7:50:37 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    GRI Bio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Kelly Leanne

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:28 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Chaturvedi Vipin

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:17 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Hertz Walter Marc

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:06 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Simpson Camilla V

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:57:55 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Baker David Charles

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:57:45 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Szekeres David Leslie

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:57:34 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Rongen Roelof

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:57:23 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    GRI Bio Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

      Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621's potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week interim analysis (n=24) in ongoing Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) anticipated in Q2 2025 LA JOLLA, CA, May 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pr

      5/22/25 8:00:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio to Participate in the Virtual Investor Closing Bell Series

      Live webcast on Wednesday, May 28th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET. As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submi

      5/21/25 9:15:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

      Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET LA JOLLA, CA, May 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21, 2025 at 2:40 PM ET. Click here to register for the event. A live webcast of the fireside chat will be accessible

      5/16/25 9:15:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

      Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF")  Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) and over two-thirds enrollment completed for the overall trial Cash runway expected to fund operations through Q3 2025 LA JOLLA, CA, May 15, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the

      5/15/25 8:35:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")

      The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial Results on track for interim data in Q2 2025 and topline data in Q3 2025 Management releases "What This Means" segment discussing the interim biomarker data; Access Here LA JOLLA, CA, May 08, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the

      5/8/25 8:45:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")

      Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled  Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 2025 LA JOLLA, CA, May 07, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that enrollment for the 6 week interim analysis is complete with 24 of the 36 planned patients randomized in its ongoing Phase 2a study evaluati

      5/7/25 9:15:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

      LA JOLLA, CA, April 16, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been selected for poster presentation in a poster discussion session at the 2025 ATS International Conference being held May 18-21, 2025 in San Francisco, CA.Details of the presentation are as follows:Title: Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary FibrosisPoster Board Numbe

      4/16/25 8:35:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Announces Closing of $5.0 Million Public Offering

      LA JOLLA, CA, April 02, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of common stock, short-term Series E-2 warrants to purchase up to 1,388,888 shares of common stock and short-term Series E-3 warrants to purchase up to 1,388,888 shares of common stock (all th

      4/2/25 4:05:00 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Announces Pricing of $5.0 Million Public Offering

      LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a public offering of an aggregate of 1,388,888 shares of its common stock (or common stock equivalents in lieu thereof), Series E-1 warrants to purchase up to 1,388,888 shares of common stock, short-term Series E-2 warrants to purchase up to 1,388,888 shares of common stock and short-term Series E-3 warrants to purchase up to 1,388,888 shares of common stock (all the warrants, collectivel

      4/1/25 11:15:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")

      The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated Interim biomarker data on track for Q2 2025 and topline results expected Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("N

      4/1/25 9:00:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    GRI Bio Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Connect Biopharma Announces New Leadership and Chair of the Board of Directors

      Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cel

      6/12/24 4:15:00 PM ET
      $CNTB
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer

      - Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm LA JOLLA, CA, April 25, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the appointment of Leanne Kelly as its Chief Financial Officer. Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce

      4/25/23 8:45:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care